Document is current
Any future updates will be listed below
-
Authors
Dahary, Dvir
Golan, Yaron
Mazor, Yaron
Zelig, Ofer
Barshir, Ruth
Twik, Michal
Iny Stein, Tsippi
Rosner, Guy
Kariv, Revital
Chen, Fei
Zhang, Qiang
Shen, Yiping
Safran, Marilyn
Lancet, Doron
Fishilevich, Simon http://orcid.org/0000-0003-1167-1638
-
Funding
Funding for this research was provided by:
Weizmann Institute of Science (Crown Human Genome Center)
LifeMap Sciences Inc.
EU grant from PIONEER, a European Network of Excellence for Big Data in Prostate Cancer
National Key Research and Development Program (2018YFC1002501)
Major Research Plan of the Provincial Science and Technology Foundation of Guangxi (AB16380214)
- License Information
-
More Information
Article History
Received: 16 July 2019
Accepted: 15 December 2019
First Online: 30 December 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: YG and YM are CEO and Vice President respectively (and co-founders) of LifeMap Sciences Inc., California, USA (LMS), OZ is the senior software engineer and DD is the clinical genetics product manager at LMS. LMS holds an exclusive license from the Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science (WIS), to market GeneCards Suite products, which are derived from the research of DL’s group at WIS, which is supported, among others, by a grant from LMS. SF, MS, RB, MT, and TIS are members of DL’s group. All authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
